Liposarcoma News and Research

RSS
Targeting HDAC2 reduces MDM2 expression and has anti-tumor effects in dedifferentiated liposarcoma

Targeting HDAC2 reduces MDM2 expression and has anti-tumor effects in dedifferentiated liposarcoma

Harvard chemists achieve landmark in drug discovery with synthesis of potent anti-cancer agent

Harvard chemists achieve landmark in drug discovery with synthesis of potent anti-cancer agent

Study identifies promising cancer target for liposarcoma

Study identifies promising cancer target for liposarcoma

Different levels of two molecules from same family can influence prognosis of liposarcoma

Different levels of two molecules from same family can influence prognosis of liposarcoma

Scientists receive critical funding to study treatments for three deadly cancers

Scientists receive critical funding to study treatments for three deadly cancers

Early study of experimental vaccine shows escalating immune response in patients with sarcoma

Early study of experimental vaccine shows escalating immune response in patients with sarcoma

Study suggests how existing and emerging immunotherapy treatments could be successful for sarcomas

Study suggests how existing and emerging immunotherapy treatments could be successful for sarcomas

Common signaling pathway may control formation of tumor cells in fat, reveals Purdue study

Common signaling pathway may control formation of tumor cells in fat, reveals Purdue study

Experts to analyse latest advances in diagnosis, treatment of soft tissue sarcoma at PharmaMar seminar

Experts to analyse latest advances in diagnosis, treatment of soft tissue sarcoma at PharmaMar seminar

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Halaven (eribulin mesylate) approved for treatment of liposarcoma

Halaven (eribulin mesylate) approved for treatment of liposarcoma

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Janssen granted Priority Review from FDA for YONDELIS (trabectedin) NDA to treat STS patients

Janssen granted Priority Review from FDA for YONDELIS (trabectedin) NDA to treat STS patients

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Janssen submits YONDELIS NDA for treatment of advanced soft tissue sarcoma

Janssen submits YONDELIS NDA for treatment of advanced soft tissue sarcoma

Study reports racial, ethnic differences in incidence of soft tissue sarcomas in young adults, adolescents

Study reports racial, ethnic differences in incidence of soft tissue sarcomas in young adults, adolescents

ATSP-7041 stapled peptide activates p53, suppresses tumor growth in animal models

ATSP-7041 stapled peptide activates p53, suppresses tumor growth in animal models

Affymetrix introduces new OncoScan FFPE Assay Kit

Affymetrix introduces new OncoScan FFPE Assay Kit

New research may help clinicians determine factors that increase risk of blood clots after surgery

New research may help clinicians determine factors that increase risk of blood clots after surgery